Percent with a Fragility Fracture Filling Prescription for an Osteoporosis Drug within Six Months
  • Print
  • PDF
  • Embed

    Copy the following code and paste it into your website in order to display the current report.

  • Download to Excel

Customize Report

    • YEAR:

    Choose Locations

    [clear all] [select all] Selected Locations:

      Choose Indicator(s)

      Select one or more indicators
      • TOPIC:
      • INDICATOR:
      • YEAR:

      [clear all] Selected Indicators:


    (Click a region name to the left to view its profile)
    Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware District of Columbia Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington West Virginia Wisconsin Wyoming National Average 90th Percentile 50th Percentile 10th Percentile
    Percent with a Fragility Fracture Filling Prescription for an Osteoporosis Drug within Six Months
    (Year: 2006-2010; Region Levels: State)
    15.4% na 14.2% 13.8% 16.6% 17.3% 12.0% 13.3% na 14.4% 13.8% 28.0% 9.9% 13.6% 16.9% 14.6% 15.8% 12.7% 15.4% 10.7% 13.3% 13.2% 13.3% 12.3% 13.8% 14.0% 17.3% 13.4% 16.4% 12.1% 10.9% 15.8% 15.0% 13.8% 14.6% 14.4% 16.0% 15.2% 13.6% 12.7% 15.1% 13.5% 14.9% 15.3% 13.0% 11.7% 11.9% 14.1% 12.8% 13.6% 13.8% 14.3% 16.6% 13.8% 11.9%
        • Patients were included in the fragility fracture cohort if they (1) experienced a fracture of the hip, distal forearm or humerus between 5/1/2006 and 12/31/2009, (2) were continuously enrolled in fee-for-service Medicare Parts A and B for at least 36 months preceding the index fracture and at least 12 months following the fracture, (3) were alive and continuously enrolled in and used (one or more fill record) a stand-alone Medicare Part D plan for at least 6 months following the fracture, (4) did not have an identically-defined fragility fracture in the 36 months preceding the index fracture, (5) were predominantly community dwelling (not hospitalized for more than 90 days and had no prescriptions filled by a long-term care pharmacy type) in the first 6 months following index fracture, (6) had no cancer diagnosis (other than non-melanoma skin cancer), hospice enrollment, or managed Medicare enrollment at any time in claims records analyzed.

        • All medication use measures were based on Part D event fill records for the time frame specific to each cohort’s observation. The Lexi-Data Basic database (Lexicomp) was used to obtain the drug name, dose, brand or generic status, and active ingredient according to the National Drug Code (NDC).


    © 2018 The Trustees of Dartmouth College | 35 Centerra Parkway, Lebanon, NH 03766 | (603) 653-0800

    The Dartmouth Atlas of Health Care is based at The Dartmouth Institute for Health Policy and Clinical Practice and is supported by a coalition of funders led by the Robert Wood Johnson Foundation, including the WellPoint Foundation, the United Health Foundation, the California HealthCare Foundation, and the Charles H. Hood Foundation.